- 期刊
Rescula as an Alternative Therapy for Beta-Blockers with Long-Term Drift Effect in Glaucoma Patients
以Rescula取代漸失效的Beta-blockers來治療青光眼之成效－原著
摘要
The purpose of this study was to evaluate both the intraocular pressure (IOP)-decreasing and neuroprotective effects of Rescula (0.12% unoprostone isopropyl) as an alternative therapy to beta-blockers with a long-term drift effect in patients with glaucoma. Twenty-eight patients with unilateral or bilateral glaucoma were treated with Rescula instead of the original beta-blocker therapy. IOP was measured using a Goldmann applanation tonometer, and visual field defects were evaluated quantitatively by Humphrey automatic perimetry central 30-2 threshold test. The mean follow-up time was at least 1 year. Rescula achieved a significant (p=0.00001) and long-lasting reduction in IOP (from 20.78±2.71 to 17.14±2.70 mmHg) in patients with open-angle glaucoma after 12 months of follow-up. It also demonstrated a significant (p=0.02) IOP-reducing effect (from 20.67±3.60 to 16.36±3.67 mmHg) in patients with angleclosure glaucoma 12 months later. The mean deviation of visual field defects changed from –13.27 dB baseline to –10.64 dB at 12 months as evaluated by Humphrey field analyzer Ⅱ central 30-2 threshold test after Rescula; however, there was no statistical difference (p=0.098). Our results showed that Rescula has a significant IOP-reducing effect as an alternative therapy to beta-blockers with long-term drift effect in patients with open-angle and angle-closure glaucoma. However, a neuroprotective effect to prevent further progression of the visual field defect in patients with glaucoma was not demonstrated in this study.
並列摘要
The purpose of this study was to evaluate both the intraocular pressure (IOP)-decreasing and neuroprotective effects of Rescula (0.12% unoprostone isopropyl) as an alternative therapy to beta-blockers with a long-term drift effect in patients with glaucoma. Twenty-eight patients with unilateral or bilateral glaucoma were treated with Rescula instead of the original beta-blocker therapy. IOP was measured using a Goldmann applanation tonometer, and visual field defects were evaluated quantitatively by Humphrey automatic perimetry central 30-2 threshold test. The mean follow-up time was at least 1 year. Rescula achieved a significant (p=0.00001) and long-lasting reduction in IOP (from 20.78±2.71 to 17.14±2.70 mmHg) in patients with open-angle glaucoma after 12 months of follow-up. It also demonstrated a significant (p=0.02) IOP-reducing effect (from 20.67±3.60 to 16.36±3.67 mmHg) in patients with angleclosure glaucoma 12 months later. The mean deviation of visual field defects changed from –13.27 dB baseline to –10.64 dB at 12 months as evaluated by Humphrey field analyzer Ⅱ central 30-2 threshold test after Rescula; however, there was no statistical difference (p=0.098). Our results showed that Rescula has a significant IOP-reducing effect as an alternative therapy to beta-blockers with long-term drift effect in patients with open-angle and angle-closure glaucoma. However, a neuroprotective effect to prevent further progression of the visual field defect in patients with glaucoma was not demonstrated in this study.